Bruker (BRKR)
(Delayed Data from NSDQ)
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Jack Henry (JKHY) Q2 Earnings & Revenues Beat, Rise Y/Y
by Zacks Equity Research
Jack Henry's (JKHY) second-quarter fiscal 2022 results benefit from strength across Core, Complementary, Corporate and Payments segments.
Carrier (CARR) Q4 Earnings & Sales Beat Estimates, Rise Y/Y
by Zacks Equity Research
Carrier's (CARR) fourth-quarter results benefit from solid momentum across HVAC, transport refrigeration, and Fire and Security.
Teradata (TDC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Teradata's (TDC) fourth-quarter 2021 results benefit from customers' migration to Vantage in the cloud. Yet, a decline in perpetual and consulting revenues remains a headwind.
Bruker (BRKR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMETEK (AME) Q4 Earnings & Sales Beat Estimates, Rise Y/Y
by Zacks Equity Research
AMETEK's (AME) fourth-quarter results reflect solid momentum in the EIG and EMG segments.
FormFactor (FORM) Q4 Earnings Beat, Revenues Increase Y/Y
by Zacks Equity Research
FormFactor's (FORM) fourth-quarter 2021 earnings are driven by strong demand for DRAM, Flash and Systems.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 19.07% and 9.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.
Is Axcelis Technologies (ACLS) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Here is how Axcelis Technologies (ACLS) and Bruker (BRKR) have performed compared to their sector so far this year.
Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research
by Zacks Equity Research
Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.
Is Hewlett Packard Enterprise (HPE) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how Hewlett Packard Enterprise (HPE) and Bruker (BRKR) have performed compared to their sector so far this year.
Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.
Bruker (BRKR) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest In Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.
Bruker (BRKR) Advances in Proteomics Workflow With New Pacts
by Zacks Equity Research
Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.
Bruker (BRKR) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Bruker (BRKR) reports better-than-expected earnings and revenues for the third quarter of 2021 on geographical performance driving the top line.
Bruker (BRKR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 40.00% and 5.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line
by Zacks Equity Research
According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.
Badger Meter's (BMI) Q3 Earnings Beat on Top-Line Growth
by Zacks Equity Research
Badger Meter (BMI) reports strong third-quarter 2021 results with net earnings and revenues increasing year over year, driven by healthy order momentum and higher adoption of digital solutions.
Thermo Fisher (TMO) Boosts COVID Testing With Wastewater Kit
by Zacks Equity Research
Thermo Fisher's (TMO) wastewater surveillance method is set to identify asymptomatic carriers on college campuses to monitor regional spread among communities.
After Plunging 14% in 4 Weeks, Here's Why the Trend Might Reverse for Bruker (BRKR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Bruker (BRKR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bruker (BRKR) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.
Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.